Stereotactic body radiation therapy in the treatment of cancer patients with oligometastatic disease: a real world study
-
Milica Stefanovic [1] ; Gemma Calvet [1] ; Héctor Pérez-Montero [1] ; Anna Esteve [2] ; Montse Ventura Bujalance [1] ; Arturo Navarro-Martín [1] ; Maria Dolores Arnaiz Fernández [1] ; Ferran Ferrer González [1] ; Susanna Marin Borras [1] ; Alicia Lozano Borbalas [1] ; Miriam Nuñez Fernandez [1] ; Miquel Macia Garau [1] ; Anna Lucas Calduch [1] ; Ferran Guedea Edo [1]
-
[1] Hospital Duran i Reynals
Hospital Duran i Reynals
Barcelona, España
-
[2] Hospital Universitari Germans Trias i Pujol
Hospital Universitari Germans Trias i Pujol
Barcelona, España
-
- Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 25, Nº. 1 (January), 2023, págs. 199-206
- Idioma: inglés
- Texto completo no disponible (Saber más ...)
-
Resumen
Purpose Stereotactic body radiation therapy (SBRT) is a treatment modality with curative intent for oligometastatic cancer patients, commonly defined by a low-burden metastatic disease with 1–5 systemic metastases. Better knowledge of the clinical profile and prognostic factors in oligometastatic cancer patients could help to improve the selection of candidates who may obtain most benefits from SBRT. The objective of this study was to describe the clinical data and outcome in term of overall survival (OS) of patients with oligometastatic disease treated with SBRT over a 6-year period.
Methods From 2013 to 2018, 284 solid tumor cancer patients with 1–5 oligometastases underwent SBRT at a large university-affiliated oncological center in Barcelona, Spain. Variables related to the patient profile, tumor, oligometastatic disease, and treatment were evaluated.
Results A total of 327 metastatic tumors were treated with SBRT. In 65.5% of cases, metachronous tumors were diagnosed at least 1 year after diagnosis of the primary tumor. The median age of the patients was 73.9 years and 66.5% were males. The median follow-up was 37.5 months. The most common primary tumors were lung and colorectal cancer, with lung and bone as the most commonly treated metastatic sites. Ninety-three percent of patients showed a Karnofsky score (KPS) between 80 and 100. Adenocarcinoma was the most common histological type. The median overall survival was 53.4 months, with 1-, 2- and 5-year survival rates of 90.5%, 73.9% and 43.4%, respectively. Overall survival rates of breast (67.6 months, 95% CI 56.4–78.9), urological (63.3 months, 95% CI 55.8–70.8), and colorectal (50.8 months, 95% CI 44.2–57.4) tumors were higher as compared with other malignancies (20 months, 95% CI 11.2–28.8 months) (p < 0.001). Patients with Karnofsky score (KPS) of 90 and 100 showed a significantly better survival than those with impaired performance status (p = 0.001).
Conclusion SBRT appears to be well tolerated and safe approach in oligometastatic patients. Patients with good performance status and with primary breast, urological and colorectal cancer have higher OS compared with other malignancies. More studies are necessary to evaluate the prognostic factors in oligometastatic disease (OMD) in order to select patients who could benefit more from this therapeutic approach.
